Ettinger D.S.,Sidney Kimmel Comprehensive Cancer Center |
Akerley W.,University of Utah |
Borghaei H.,Fox Chase Cancer Center |
Chang A.C.,University of Michigan |
And 31 more authors.
JNCCN Journal of the National Comprehensive Cancer Network | Year: 2013
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail. Copyright © 2013 by the National Comprehensive Cancer Network.
PubMed | University of Houston, University of Texas Anderson Cancer Center, University Of Texas Md Anderson Cancer Center Electronic Address, Harvard University and 2 more.
Type: | Journal: PM & R : the journal of injury, function, and rehabilitation | Year: 2017
Pancytopenia, immunosuppression and other factors may put patients with multiple myeloma at risk for medical complications. These patients often require inpatient rehabilitation. No prior studies have looked at risk factors for return to the primary acute care service of this patient population.To determine the percentage of and factors associated with return to the primary acute care service of multiple myeloma rehabilitation inpatients.Retrospective review SETTING: Acute inpatient rehabilitation unit within a National Cancer Institute Comprehensive Cancer Center PARTICIPANTS: All patients with multiple myeloma admitted to the inpatient rehabilitation unit between March 1, 2004 through February 28, 2015.Return to the primary acute care service was analyzed with demographic information, multiple myeloma characteristics, medications, laboratory values and hospital admission characteristics.One hundred and forty three inpatient rehabilitation admissions were found during the study period. After removing multiple admissions of the same patients and planned transfers to the primary acute care service, 122 admissions were analyzed. Thirty two (26%) patients transferred back to the primary acute care service for unplanned reasons. Multivariate analysis revealed male sex and thrombocytopenia as significantly associated with return to the primary acute care service. The median survival of patients who transferred back to the inpatient primary acute care service was 180 days versus 550 days for those who did not (p<.001).Due to their medical fragility, clinicians caring for multiple myeloma rehabilitation inpatients should maintain close contact with the primary oncology service. Factors associated with an increased risk of transfer back to the primary acute care service include male sex and thrombocytopenia.
Martinez-Velez N.,University of Navarra |
Xipell E.,University of Navarra |
Jauregui P.,University of Navarra |
Zalacain M.,University of Navarra |
And 13 more authors.
Journal of Bone and Mineral Research | Year: 2014
Osteosarcoma is the most common malignant bone tumor in children and adolescents. The presence of metastases and the lack of response to conventional treatment are the major adverse prognostic factors. Therefore, there is an urgent need for new treatment strategies that overcome both of these problems. Our purpose was to elucidate whether the use of the oncolytic adenovirus Δ24-RGD alone or in combination with standard chemotherapy would be effective, in vitro and in vivo, against osteosarcoma. Our results showed that Δ24-RGD exerted a potent antitumor effect against osteosarcoma cell lines that was increased by the addition of cisplatin. Δ24-RGD osteosarcoma treatment resulted in autophagy in vitro that was further enhanced when combined with cisplatin. Of importance, administration of Δ24-RGD and/or cisplatin, in novel orthotopic and two lung metastatic models in vivo resulted in a significant reduction of tumor burden meanwhile maintaining a safe toxicity profile. Together, our data underscore the potential of Δ24-RGD to become a realistic therapeutic option for primary and metastatic pediatric osteosarcoma. Moreover, this study warrants a future clinical trial to evaluate the safety and efficacy of Δ24-RGD for this devastating disease. © 2014 American Society for Bone and Mineral Research.